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Abstract
AIM: To evaluate the long-term risk of gastroduodenal 
ulcer and cardiovascular events induced by celecoxib 
in a population-based, randomized, double-blind, 
placebo-controlled study. 
METHODS: From 2004 to 2006, a total of 1024 
Chinese patients (aged 35 to 64 years) with severe 
chronic atrophic gastritis, intestinal metaplasia or 
dysplasia were randomly assigned to receive 200 mg 
of celecoxib twice daily or placebo in Linqu County 
(Shandong Province, China), a high-risk area of gastric 
cancer. All gastroduodenal ulcer and cardiovascular 
events occurred were recorded and the patients were 
followed up for 1.5 years after treatment. At the end 
of the trial, a systematic interview survey about other 
adverse events was conducted. 
RESULTS: Gastroduodenal ulcer was detected in 19 
of 463 (3.72%) patients who received celecoxib and 
17 of 473 (3.31%) patients who received placebo, 
respectively (odds ratio = 1.13, 95% CI = 0.58-2.19). 
Cardiovascular (CV) events occurred in 4 patients who 
received celecoxib and in 5 patients who received 
placebo, respectively. Compared with those who 
received placebo, patients who received celecoxib had 
no significant increase in occurrence of CV events (hazard 
ratio = 0.84, 95% CI = 0.23-3.15). Among the adverse 
events acquired by interview survey, only the frequency 
of bloating was significantly higher in patients treated 
with celecoxib than in those treated with placebo. 
CONCLUSION: Treatment of gastric cancer with 
celecoxib is not associated with increased risk of 
gastroduodenal ulcer and cardiovascular events. 
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION 
Celecoxib, approved by the US Food and Drug 
Administration (FDA) in 1998 for osteoarthritis and 
rheumatoid arthritis, is a cyclooxygenase-2 (COX-2) 
inhibitor. Owing to the selective inhibition of  COX-2, 
this drug provides similar anti-inflammatory effects 
and a reduced risk of  gastrointestinal complications in 
osteoarthritis and rheumatoid arthritis patients compared 
with nonsteroidal anti-inflammatory drugs (NSAIDs)[1,2], 
which inhibit both COX-1 and COX-2. In addition, 
celecoxib, a selective inhibitor of  COX-2, can block 
tumor growth by its antiangiogenic and proapoptotic 
effects, suggesting that it can be used in the prevention 
and treatment of  cancers[3-5]. 
However, it was reported that rofecoxib, also a 
COX-2 inhibitor, is associated with gastrointestinal toxic 
effects and cardiovascular (CV) events[6,7]; But, it has no 
gastrointestinal toxicity[8]. The conflicting results have 
raised the concern about the safety of  celecoxib[9,10]. In 
2005, the FDA Advisory Committee concluded that 
the adverse events of  celecoxib are less than those of  
rofecoxib[11]. Therefore, we studied the safety issue of  
celecoxib. Gastroduodenal ulcer and CV events induced 
by celecoxib are reported in this paper. 
MATERIALS AND METHODS 
Study population 
In 2004, a total of  1024 subjects, randomly selected from 
12 villages of  Linqu County (Shandong Province, China), 
participated in this study. Their age was 35-64 years. All 
subjects received a brief  physical examination and their 
medical history was recorded. Subjects were ineligible 
if  they had a history of  stroke within two years, angina 
or congestive heart failure or myocardial infarction 
within one year, neoplastic diseases in the previous 
10 years, esophageal or gastric surgery, inflammatory 
bowel disease, or bleeding diathesis, paracetamol allergy 
or hypersensitivity to aspirin, or other life-threatening 
illness. The remainders received 13C-urea breath test 
(13C-UBT) and gastroscopic examination with biopsies 
from 5 standard sites of  the stomach. Only those who 
had Helicobacter pylori (H pylori) infection and a histological 
diagnosis of  severe chronic atrophic gastritis (CAG), 
intestinal metaplasia (IM) or dysplasia (DYS) were 
enrolled in the intervention trial. A written informed 
consent was obtained from each participant and the trial 
was approved by the Institutional Review Board (IRB) 
of  Peking University School of  Oncology (PUSO). 
Study design and randomization 
Subjects were randomly assigned to received antibiotics 
and/or celecoxib or their placebo in a 2 × 2 factorial 
design. Finally, the subjects were divided into four 
groups. Group 1 received anti-H pylori treatment in the 
first week followed by 200 mg celecoxib twice daily for 
24 mo, group 2 received anti-H pylori treatment in the 
first week followed by a look-alike celecoxib placebo 
for 24 mo, group 3 received a look-alike anti-H pylori 
placebo in the first week followed by celecoxib twice 
daily for 24 mo, group 4 received a look-alike anti-H 
pylori placebo in the first week followed by a look-alike 
celecoxib placebo for 24 mo. We only observed and 
evaluated the risk of  cardiovascular and other adverse 
events in the celecoxib and placebo groups (Figure 1). 
Both the participants and investigators were blinded to 
the treatment. Randomization of  treatment assignments 
was generated at Westat Inc. in the US after eligibility 
was determined. 
From March 16 to 30, 2004, the eligible participants 
were given a triple therapy with 20 mg omeprazole, 
1 g amoxicillin and 500 mg clarithromycin or placebo 
twice daily for 7 d to eradicate their H pylori infection. 
Then 200 mg of  celecoxib or placebo twice daily was 
given orally from April 8, 2004 to May 6, 2006, except 
for April 2005 because of  the interim gastroscopic 
examination. 
Follow-up 
During the period of  study, labeled pill bottles of  
celecoxib or placebo were distributed to participants 
in each village by PUSO staff  and trained field staff  
each month. The field staff  visited each participant 
twice a month to monitor treatment-related events and 
to promote pill compliance in the entire duration of  
the study. The staff  counted and recorded the number 
of  pills remaining in each bottle before the new pill 
bottles were distributed each month. If  a subject was 
not at home during the staff  visit, an evening visit was 
scheduled. A subject was considered compliant if  the pill 
bottle was empty at the end of  that month. If  a subject 
was unable to be contacted at the time of  counting pills, 
he or she was considered non-compliant. 
Adverse events 
Gastroduodenal ulcer was detected in 2005 and 
2006 by the same group of  PUSO physicians and 
gastroenterologists. Gastroscopic procedures, including 
biopsy samples taken from seven standard sites of  
stomach and histopathologic criteria, have been 
described elsewhere[12]. The gastroenterologist and 
pathologist were blinded to the subjects’ intervention. 
The CV events were defined as fatal or nonfatal 
myocardial infarction, ischemic and hemorrhagic stroke 
as previously described[13]. When visiting the participants, 
investigators recorded the CV events and other 
complaints of  the participants. While investigators were 
absent, participants-reported symptoms were recorded 
by doctors in village clinics. All the CV events were 
diagnosed in local hospitals. 
Other non-adjudicated adverse events were acquired 
by an interview among all the subjects at the end of  the 
trial in May 2006. All the subjects’ symptoms in the past 
two years were inquired and recorded by the trained 
interviewers, checked and categorized by two physicians 
in a blinded fashion after completion of  the survey. 
If  the symptoms were related to treatment, PUSO 
physicians and field staff  paid a close attention to the 
www.wjgnet.com
4536      ISSN 1007-9327      CN 14-1219/R      World J Gastroenterol     July 28, 2008      Volume 14    Number 28
subjects for at least 2 mo and these subjects received 
continuous treatment if  the symptoms were aggravated. 
Statistical analysis 
This study was designed to achieve a significant level 
of  95% (< 0.05) and a power of  90% to detect a 20% 
regression of  pre-malignant lesions, based on the 
background of  80% prevalence of  gastric atrophy. At 
least 120 subjects were required in each group in order 
to detect a significant difference between the different 
treatment groups. 
All data analyses were performed in a blinded 
fashion. The relative risks (with 95% confidence 
intervals) of  gastroduodenal ulcer were analyzed using 
logistic regression by adjusting gender, age, smoking 
and drinking. The rate of  CV events was determined 
and multivariate hazard ratio (HR) was calculated using 
the Cox proportional-hazard model. All P values were 
two-sided, and P < 0.05 was considered statistically 
significant. All analyses were performed with SAS 
software, version 8.2. 
RESULTS 
The 1024 participants were divided into celecoxib 
treatment group (n = 511) and placebo treatment group 
(n = 513). The baseline characteristics were balanced 
between the two groups (Table 1). During the two-year 
period of  treatment, 88 participants who were relatively 
evenly distributed between the two groups withdrew 
from the study (Figure 1). The compliance rate was 
90.61% in the celecoxib treatment group and 92.20% in 
the placebo treatment group, respectively. 
From April 2004 to May 2006, gastroduodenal ulcer 
was detected in 19 of  463 (3.72%) participants of  the 
celecoxib treatment group and in 17 of  473 (3.31%) 
participants of  the placebo treatment group, respectively. 
The odds ratio (OR) was 1.13 (95% CI = 0.58-2.19, 
Table 2). 
During the entire period of  follow-up, CV events 
occurred in 4 participants of  the celecoxib treatment 
group and in 5 participants of  the placebo treatment 
group, respectively (Table 2). Compared with the placebo 
treatment group, the celecoxib treatment group had no 
www.wjgnet.com
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Figure 1  Trial profile.
significant increase in occurrence of  CV events (HR = 
0.84, 95% CI = 0.23-3.15). 
The main nonadjudicated side effects are listed 
in Table 2. Except for bloating (OR = 2.85, 95% CI 
= 1.19-6.84), there were no significant differences in 
the frequency of  other nonadjudicated adverse events 
between the two groups. 
DISCUSSION 
In this study, gastroduodenal ulcer and CV events 
occurred in the subjects who took 200 mg celecoxib 
twice daily. 
Two previous tr ials addressed the possibil i ty 
that celecoxib has a lower rate of  gastrointestinal 
complications than NSAIDs[14,15]. It was reported that 
the annual incidence rate of  upper gastrointestinal 
complications and symptomatic ulcers is significantly 
lower in the celecoxib treatment group than in the 
combined diclofenac and ibuprofen treatment group 
(2.08% vs 3.54%; P = 0.02) after 6 mo of  treatment[14]. It 
has been shown that the incidence rate of  gastric ulcer in 
the celecoxib treatment group and diclofenac treatment 
group is 18% and 34%, respectively (P < 0.001), and 
the incidence rate of  duodenal ulcer is 5% and 11%, in 
the celecoxib treatment group and diclofenac treatment 
group, respectively (P < 0.009)[15]. 
Although the distinct role of  celecoxib in ulcer is 
still unclear[16], most studies suggested that celecoxib is 
not associated with gastric or duodenal ulcer[17-19]. Our 
trial compared the effects of  celecoxib and placebo on 
gastroduodenal ulcer, and the risk of  gastroduodenal 
ulcer was not increased after treatment with 200 mg 
celecoxib daily compared with placebo. 
The association between celecoxib and CV events 
was still debatable in our study. It was reported that a 
single dose of  400 mg celecoxib daily and placebo does 
not induce excess CV risk[20]. However, it was reported 
that 800 mg celecoxib increases the risk of  death due to 
cardiovascular disease, myocardial infarction, stroke, or 
heart failure[21]. 
T h e m e ch a n i s m u n d e r l y i n g t h e p o t e n t i a l 
cardiovascular risk of  COX-2 inhibitors is not fully 
understood. Although the imbalance caused by 
COX-2 inhibitors suppressing the COX-2 dependent 
prostacyclin production in endothelial cells without 
affecting the synthesis of  platelet-derived thromboxane 
A2, may promote thrombosis and increase the risk 
of  CV events[22-24], the extent of  instability to serum 
thromboxane and platelet function can be influenced 
by many factors, such as different doses of  COX-2 
inhibitors, variability among patients[16]. 
In this study, different dose-effects of  celecoxib on 
cardiovascular risk were observed. The dose of  800 mg 
celecoxib daily could increase the CV risk. However, 400 
mg celecoxib daily did not increase the CV risk, suggesting 
that it can be used in the treatment of  gastric ulcer. 
In the present study, the frequency of  bloating 
was higher in the celecoxib treatment group than in 
the placebo treatment group. However, the CV events 
were mild and tolerable, and none of  the participants 
withdrew from this trial. 
In conclusion, increases in gastroduodenal ulcer and 
CV events do not occur in subjects who take 200 mg 
celecoxib twice daily for two years. Celecoxib can be 
used in prevention and treatment of  gastric cancer. 
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 COMMENTS
Background
Celecoxib, a cyclooxygenase-2 inhibitor, is widely used as an analgesic and 
anti-inflammatory agent. In addition, it can prevent cancer. However, it is 
necessary to evaluate the risk of gastroduodenal ulcer and cardiovascular 
events, particularly in population-based studies.
Research frontiers
No increase in gastroduodenal ulcer and cardiovascular (CV) events were 
found in the subjects who took 200 mg celecoxib twice daily for two years. 
Innovations and breakthroughs
This paper firstly reports an assessment of celecoxib-related gastroduodenal 
ulcer and cardiovascular events in Chinese population.
Applications 
Celecoxib (200 mg twice daily for two years) can prevent and treat gastric 
cancer in Chinese population.
Peer review
The authors documented the absence of adverse effects of prolonged celecoxib 
administration at gastroduodenal and cardiovascular level in Chinese patients. 
The study was well designed and the results are reliable.
Table 2  Incidence and risk of side effects in two groups 
Celecoxib, 
n  (%)
Placebo, 
n  (%)
OR (95% CI) 
Gastroduodenal ulcer 19 (3.72) 17 (3.31) 1.13 (0.58-2.22) 
CV events   4 (0.86)   5 (1.06) 0.84 (0.23-3.15) 
Main nonadjudicated 
side effects 
   Abdominal pain   8 (1.73) 13 (2.75) 0.62 (0.26-1.52) 
   Bloating 19 (4.10)   7 (1.48) 2.85 (1.19-6.84) 
   Constipation   9 (1.94) 15 (3.17) 0.61 (0.26-1.40) 
   Diarrhea 24 (5.18) 24 (5.07) 1.02 (0.57-1.83) 
   Dizziness 25 (5.40) 36 (7.61) 0.69 (0.41-1.17) 
   Gastric spasmus 15 (3.24) 15 (3.17) 1.02 (0.49-2.12) 
   Headache 26 (5.62) 23 (4.86) 1.16 (0.65-2.07) 
   Heartburn 29 (6.26) 23 (4.86) 1.31 (0.75-2.30) 
   Loss of appetite 25 (5.40) 16 (3.38) 1.63 (0.86-3.10) 
   Muscle pain   55 (11.88)   70 (14.80) 0.78 (0.53-1.13) 
   Nausea 14 (3.02) 17 (3.59) 0.84 (0.41-1.72) 
   Pain in the chest 16 (3.46) 17 (3.59) 0.96 (0.48-1.92) 
   Palpitations 22 (4.75) 16 (3.38) 1.43 (0.74-2.75) 
Table 1  Baseline characteristics of 1024 participants
Celecoxib, n  (%) Placebo, n  (%) P  
Male 238 (46.58) 235 (45.81) 0.81 
Age (yr, means ± SD) 52.94 ± 6.51 52.93 ± 6.48 0.97 
Smoking 146 (28.57) 142 (27.68) 0.75 
Drinking 172 (33.66) 175 (34.11) 0.88 
Hypertension 155 (30.33) 160 (31.19) 0.77 
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